ࡱ> CEB %bjbjtWtW 50=g=g lllllD6 $~ <ElllL!!!ll!!!!4W,sF!b0! 4 ! l!!4 X 2: @Supplementary Table 1. Characteristics of the randomized controlled trials included in the Asian subgroup. First author Trial duration Asian Diabetes duration Age Male (%) Number of Dosage HbA1c at baseline (%) BMI at baseline kg/3 FPG, mmol/L (year) (weeks) patients (years) (years) patients SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET SGLT2-i MET plus MET monotherapy plus MET monotherapy plus MET monotherapy plus MET monotherapy plus MET monotherapy (mg/day) (mg/day) plus MET monotherapy plus MET monotherapy plus MET monotherapyLinong Ji 2015 18 100% 100% 6.84.5 6.84.5 56.58.3 55.89.4 55.6 55.3 223 226 CANA 100 e"1500 8.00.9 7.90.9 25.63.4 25.53.6 8.71.9 8.81.8Wenying YANG 2016 24 100% 100% 5.34.6 5.34.4 54.69.5 53.59.2 57.9 59.3 152 145 DAPA 10 e"1500 8.170.84 8.130.85 26.23.5 25.7 2.9 9.0 2.2 9.22.5 Kashiwagi 2015 24 100% 100% 7.495.67 8.055.16 5 ijk   h l XZ\PR㮮ǚv"hjEB*CJOJQJaJo(ph#hjEB*CJKHOJQJaJph&hjEB*CJKHOJQJaJo(ph1hQ&5B*CJKHOJPJQJ\_HaJph# 7hoDyhjE5B*CJKHOJPJQJ\_HaJph# 7hoDyhoDy5B*CJKHOJPJQJ\_HaJph# .k  $<&#$/IfWD` b$l '$$<&#$/IfWDj^`a$b$l  . dWD`.  Zid$<&#$/Ifb$l xkd$$IfnMM  6< 0M44 lae4p Z\Rf!$d$<&#$/1$Ifa$b$l vkd$$IfnMM  6< 0M44 lae4p RT`JLNn T!V!X!!""""L#N#P#R#T#V#X#Z#\#^#`#b#d#f#h#j#l#n#p#r###$$$$$$ڰƬ#hjEB*CJKH^J_HaJphhjECJOJQJ_HaJ hjEo(hjE&hjEB*CJKHOJQJaJo(phU&hjEB*CJKHOJQJaJo(ph&hjEB*CJKHOJQJaJo(ph# "hjEB*CJOJQJaJo(ph5RTLf!$d$<&#$/1$Ifa$b$l vkdt$$IfnMM  6< 0M44 lae4p 6.210.7 57.79.24 58.9 58.9 112 56 IPRA 50 e"1500 8.250.72 8.380.74 25.964.4 25.53.09 8.981.66 9.701.38Chieh-Hsiang Lu 2016 24 100% 100% --------- -------- -------- -------- ------- ------- ------- ------- IPRA 50 e"1500 -------- -------- -------- -------- -------- --------Kyung-AhHan 2018 24 100% 100% 11.65.9 11.336.6 57.68.26 57.47.88 50.7 48.5 73 66 IPRA 50 e"1500 7.900.69 7.920.79 25.53.07 26.13.8 8.771.6 8.851.84 CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; ERTU, ertugliflozin; IPRA, ipragliflozin; MET, metformin; BMI, body mass index; FPG, fasting plasma glucose;Data are mean SD or mean; SD, standard deviation. LNV!kd$<&#$/Ifb$l vkd$$IfnMM  6< 0M44 lae4p V!X!N#f!$d$<&#$/1$Ifa$b$l vkd$$IfnMM  6< 0M44 lae4p N#P#R#T#V#X#Z#\#^#`#b#d#f#h#j#l#vkdr$$IfnMM  6< 0M44 lae4p l#n#p#r#$x%% dWD`d$$F%H%v%x%%%hjE hjEo(hjECJOJQJaJ#hjEB*CJKH^J_HaJphhjECJOJQJ_HaJhjECJ_HaJ3182P0w A! " #$%S $$If!vh#vM:V   6< 0M5M/ /  ae4p $$If!vh#vM:V  6< 0M5M/ / ae4p $$If!vh#vM:V  6< 0M5M/ ae4p $$If!vh#vM:V  6< 0M5M/ ae4p $$If!vh#vM:V  6< 0M5M/ ae4p $$If!vh#vM:V  6< 0M5M/  / ae4p x66666668 0@P`p6888 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@66666PJ_HmH @nH @sH @tH @Z`Z Normal $1$a$(CJKHOJQJ_HaJmH nHsH tHDA D Default Paragraph Fonti@  Table Normal[:V 44l44l02 d1$$$ $[$\$^]CJOJQJo(^JaJtH (k ( 0No List PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vj\{cp/IDg6wZ0s=Dĵw %;r,qlEآyDQ"Q,=c8B,!gxMD&铁M./SAe^QשF½|SˌDإbj|E7C<bʼNpr8fnߧFrI.{1fVԅ$21(t}kJV1/ ÚQL×07#]fVIhcMZ6/Hߏ bW`Gv Ts'BCt!LQ#JxݴyJ] C:= ċ(tRQ;^e1/-/A_Y)^6(p[_&N}njzb\->;nVb*.7p]M|MMM# ud9c47=iV7̪~㦓ødfÕ 5j z'^9J{rJЃ3Ax| FU9…i3Q/B)LʾRPx)04N O'> agYeHj*kblC=hPW!alfpX OAXl:XVZbr Zy4Sw3?WӊhPxzSq]y +0R$%  ZRLV!N#l#% 8@0(  B S  ? OLE_LINK152  &LMPQ)*ijvw  $%ders !`ano|}ab !"abop}~ jiq 3333 ij  ij %Q&jEoDyA"^5T[6Mqm5+.#B;$ $l)%)D5W*G+\,f\1UD478YcEF{>H OtSEq#Xb;Y@1Z^^7?c'wga+o%Mr@ uh!yNM}~ @@ @ @UnknownG.[x Times New Roman5Symbol3. .[x ArialuMinion-RegularMalgun Gothic Semilight;(SimSun[SOG..{$ CalibriCalibriC.,.{$ Calibri LightA$BCambria Math QhӂgCyeyeZ&!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[  KP  $PoDy2!xx? 51117Aura Oh+'0X    ,8@HP51117 Normal.dotmAura3Microsoft Office Word@G@9~@&W,ye ՜.+,D՜.+,, hp|     Titled ?GKSOProductBuildVer2052-11.1.0.10314  "#$%&'()*+,-./013456789;<=>?@ADRoot Entry F>W,FData 1Table! WordDocument50SummaryInformation(2DocumentSummaryInformation8:CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q